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Available online 18 August 2016Objectives: Despite maximally tolerated statin therapy, many patients with high cardiovascular risk, with or
without heterozygous familial hypercholesterolemia may require additional low-density lipoprotein cholesterol
(LDL-C) reduction. We report pooled alirocumab (ALI) efﬁcacy and safety data from eight Phase 3 trials in 4629
hypercholesterolemia patients, receiving background statin therapy.
Material and methods: Studies were pooled by ALI dose and control: ALI 75/150 mg every 2 weeks (Q2W; dose
increased to 150 mg Q2W at Week 12 based on Week 8 LDL-C) versus ezetimibe (EZE; Pool 1) or placebo
(PBO; Pool 2), and ALI 150 mg Q2W versus PBO (Pool 3).
Results:Mean baseline LDL-C was 109 vs. 105 mg/dL (Pool 1), 129 vs. 130 mg/dL (Pool 2) and 126 vs. 125 mg/dL
(Pool 3). ALI 75/150mgQ2Wreduced LDL-C by 48.9% (vs.−19.3% EZE) and 48.6% (vs.+4.2% PBO) frombaseline
toWeek 24, and ALI 150mgQ2Wreduced LDL-C by 60.4% (vs.+0.5% PBO; all p b 0.0001). LDL-C reductionswere
sustained toWeek 104. Risk-based LDL-C goals (b70 mg/dL or b100 mg/dL) were achieved by 78.0%, 75.2%, and
79.0% (Pool 1–3) of ALI-treated patients (vs. 52.4%, 6.4%, and 8.4%, respectively, for controls) at Week 24.
Consistent reductions were observed in apolipoprotein B, non-high-density lipoprotein cholesterol, and
lipoprotein (a) (p b 0.0001 vs. control). Common adverse events in ALI-treated patients were nasopharyngitis,
injection-site reactions, upper respiratory tract infections, and inﬂuenza.
Conclusions: Alirocumab treatment signiﬁcantly reduced LDL-C in high cardiovascular risk patients, enabling
most to achieve risk-based LDL-C goals.
© 2016 Elsevier Ireland Ltd. All rights reserved.Keywords:
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Elevated low-density lipoprotein cholesterol (LDL-C) is a major risk
factor for developing and worsening of atherosclerotic cardiovascular
disease (ASCVD) [1]. LDL-C reduction is particularly important in people
deﬁned as having a high risk of CV events, including those with familial
dyslipidemia, severe hypertension, diabetes mellitus, moderate chronic
kidney disease (CKD) or a calculated SCORE risk of fatal CV disease oflerotic cardiovascular disease;
igh-density lipoprotein choles-
LDL-C, low-density lipoprotein
tein (a); Q2W, every 2 weeks;
e la Nation, 21000 Dijon, France.
.
.≥5% [2,3]. However, many of these patients do not reach LDL-C targets,
despite receiving maximally tolerated statin therapy [1,3,4].
Although LDL-C remains the primary focus of lipid-lowering therapy
(LLT), other lipoproteins, such as non-high-density lipoprotein
cholesterol (non-HDL-C) and apolipoprotein (apo) B, are also recog-
nized as important risk factors. In fact, it has been proposed that these
maymore accurately reﬂect the level of circulating atherogenic lipopro-
tein than LDL-C (calculated using the Friedewald equation) [4].
Lipoprotein(a) [Lp(a)] is an apo B-containing atherogenic lipoprotein
that predicts CV risk and is associated with aortic valvular disease
independently of LDL-C; it is recognized that statin therapy has little,
if any, effect on this parameter.
Alirocumab (a monoclonal antibody that binds to and inhibits
proprotein convertase subtilisin/kexin type 9, preventing low-density
lipoprotein receptor degradation and thereby increasing LDL-C clear-
ance) has been approved for the treatment of hypercholesterolemia in
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tolerated statin therapy [5,6]. In the USA, alirocumab is indicated for
use in adults with HeFH or clinical ASCVD who require additional low-
ering of LDL-C [6]; in Europe, approval includes adults with primary hy-
percholesterolemia (HeFH and non-familial) or mixed dyslipidemia,
with or without other LLTs, in patients unable to reach LDL-C goals
withmaximum tolerated statin. In Europe, the indication also speciﬁcal-
ly permits the use of alirocumab as monotherapy or combination ther-
apy with other LLTs in statin-intolerant patients, or for those where
statins are contraindicated [5].
Here, we present a pooled analysis of alirocumab efﬁcacy and safety
data from eight ODYSSEY Phase 3 clinical trials of up to 104 weeks in
high-risk patients (including people with HeFH, and people with
established CVD, or risk equivalents). Each trial was conducted in indi-
viduals on background statin therapy. In six of the eight studies, individ-
uals received maximally tolerated statins (accounting for 91% of the
total number of individuals included in the pooled dataset), while in
the other two studies a ﬁxed dose of background statin was used, either
atorvastatin 20–40 mg or rosuvastatin 10–20 mg. In all the individual
trials, alirocumab treatment at a dose of 75 or 150 mg every 2 weeks
(Q2W) resulted in a signiﬁcant reduction in LDL-C versus controls in pa-
tients at high CV risk with or without HeFH [7–13]. For the pooled anal-
ysis, we report on the effects of alirocumab treatment on LDL-C and
other lipid parameters, including non-HDL-C, apo B, and Lp(a).
2. Methods
2.1. Study designs and pooling strategy
This analysis includes data from eight Phase 3 randomized, double-blind, controlled
trials (Fig. 1). Methods of the individual trials have been reported previously [8,9,
11–14]. Patients were randomized to either alirocumab or control in a 2:1 ratio (1:1
ratio in the OPTIONS I and II studies) and received double-blind study treatment for
24–104 weeks.
For the purposes of the present analysis, efﬁcacy datawere analyzed in three pools ac-
cording to the alirocumab dose and control used in each individual trial. Three trialsFig. 1. Pooling strategy. For purposes of this analysis, efﬁcacy data were analyzed in three
pools according to alirocumab dose (75/150 mg or 150 mg Q2W) and control (ezetimibe
or placebo). For safety analysis, Pool 2 and Pool 3 were combined. n values refer to the
number of patients in the randomized study populations. a Maximally tolerated statin
was deﬁned as atorvastatin 40–80 mg, rosuvastatin 20–40 mg, or simvastatin 80 mg.
Fixed doses of atorvastatin 20–40 mg and rosuvastatin 10–20 mg were used in OPTIONS
I and II, respectively. b In the OPTIONS studies, dose was increased if LDL-C was ≥70 mg/
dL (prior CHD) or ≥100 mg/dL (CHD risk equivalents). CHD, coronary heart disease;
HeFH, heterozygous familial hypercholesterolemia; FH, familial hypercholesterolemia;
LDL-C, low-density lipoprotein cholesterol; LLT, lipid-lowering therapy; Q2W, every
2 weeks. Clinicaltrials.gov identiﬁers: COMBO II, NCT01644188; OPTIONS I,
NCT01730040; OPTIONS II, NCT01730053; FH I, NCT01623115; FH II, NCT01709500;
COMBO I, NCT01644175; LONG TERM, NCT01507831; HIGH FH, NCT01617655.compared alirocumab 75/150 mg Q2W versus ezetimibe (Pool 1, n = 1130), three trials
compared alirocumab 75/150 mg Q2W versus placebo (Pool 2, n = 1051), and two trials
compared alirocumab 150 mg Q2W versus placebo (Pool 3, n = 2448) (Fig. 1). In Pools 1
and 2, the alirocumab dose was increased in a blinded fashion from 75 to 150 mg Q2W at
Week 12 if Week 8 LDL-C level was ≥70 mg/dL (or ≥70 or ≥100 mg/dL, depending on CV
risk, in the OPTIONS I and II studies). Safety data were analyzed in two pools according to
control group.
2.2. Patients
The FH I, FH II, andHIGH FH studies exclusively recruited patients with HeFH andwho
were therefore at high CV risk. COMBO I and II recruited non-FH patients at high CV risk
(established CHD/CVD or CHD risk equivalents [e.g. CKD or diabetes mellitus with other
risk factors]). The other studies recruited both HeFH patients and non-FH patients at
high CV risk (as above plus people without documented CHD or CVD but with a 10-year
risk of fatal CVD ≥5% [SCORE] in the OPTIONS studies). For study entry, LDL-C at screening
had to be ≥70 or 100 mg/dL, depending on CV risk (except in LONG TERM, where LDL-C
was ≥70 mg/dL for all patients, and in HIGH FH, where LDL-C had to be ≥160 mg/dL). El-
igibility also required all patients to be receiving maximally tolerated statin, with or with-
out other LLT, which was continued throughout the study as background therapy.
Exceptions were the OPTIONS I and II trials, which used ﬁxed doses of atorvastatin
20–40 mg and rosuvastatin 10–20 mg, respectively, and COMBO II, in which no other
LLT was allowed. Maximally tolerated statin was deﬁned as atorvastatin 40–80 mg,
rosuvastatin 20–40 mg, or simvastatin 80 mg (lower doses were allowed with an
investigator-approved reason, e.g. intolerance). All studies were conducted in accordance
with the ethical principles originating from the Declaration of Helsinki and applicable
amendments laid down by the World Medical Assemblies, and the International Confer-
ence Harmonization guidelines for Good Clinical Practice. For each participating study
site, institutional reviewboard or independent ethics committee approval of the protocols
was ascertained and written informed consent was obtained from all patients.
2.3. Endpoints and statistical analysis
Efﬁcacy endpoints included the percentage change in LDL-C (calculated using the
Friedewald formula), apo B, non-HDL-C, Lp(a), triglycerides, HDL-C, and apoA1 frombase-
line to Week 12 (before possible dose increase) and Week 24 (primary endpoint in each
individual study), and the proportion of patients achieving risk-based LDL-C goals. Data
were analyzed using an intention-to-treat approach, including all lipid data regardless of
adherence to treatment. An analysis using only on-treatment data was also performed.
Least-squares mean lipid values were calculated from amixed-effects model with repeat-
ed measures to account for missing data, as described previously [15]. Adjusted means
were calculated for Lp(a) and triglycerides, withmissing values calculated bymultiple im-
putation followed by robust regression. Combined estimates were calculated for LDL-C
goal achievement, withmissing data accounted for bymultiple imputation followed by lo-
gistic regression. Safety was assessed via reporting of treatment-emergent adverse events
(TEAEs) and laboratory values. Adverse events were classed as TEAEs if they were report-
ed from the ﬁrst dose of study treatment up to the last dose plus 70 days. Descriptive sta-
tistics only were used for safety analyses (no formal statistics were planned in the study
protocols).3. Results
3.1. Patients
In total, this analysis included 4629 patients (1130 in Pool 1, 1051 in
Pool 2, and 2448 in Pool 3). Demographic and baseline characteristics
were similar for the alirocumab and control groups within the study
pools (Table 1). More patients weremale than female, and themajority
of patients were white. A history of ASCVDwas reported for the major-
ity of patients; Pool 1, 84.5% alirocumab versus 79.5% control; Pool 2,
56.5% versus 56.8%; Pool 3, 75.0% versus 77.0%, and a history of diabetes
was reported in 35.4% versus 37.4% in Pool 1, 18.9% versus 20.2% in Pool
2, and 34.7% versus 34.5% in Pool 3, respectively (Table 1). Pool 2 had the
lowest proportion of patients with diabetes or ASCVD, and this pool had
the highest baseline LDL-C values (Table 1). A greater proportion of
patients in Pool 2 had HeFH (69.9%) as the FH I and FH II studies exclu-
sively recruited patients with this condition (Table 1). Lower rates of
ASCVD, diabetes and higher LDL-C are all reﬂections of the enrichment
in FH patients. Most patients were receiving maximally tolerated statin
therapy (91%). In Pool 1, 11% of alirocumab-treated individuals were
also receiving additional LLT at study entry (vs. 12% control group)
compared with 57% and 28% of alirocumab-treated individuals in
Pools 2 and 3 (vs. 62% and 28% in respective control groups).
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The pooled alirocumab groups demonstrated signiﬁcantly greater
reductions from baseline in LDL-C atWeeks 12 and 24 versus ezetimibe
or placebo (Fig. 2). At Week 12, before potential alirocumab dose
increase in those studies utilizing the dose increase strategy, LDL-C
was reduced with alirocumab 75 mg Q2W by 49.2% (vs. 22.3% with
ezetimibe) in Pool 1 and 44.5% (vs. an increase of 4.1% with placebo)
in Pool 2; the reduction with the 150 mg Q2W dose at Week 12 was
62.6% versus an increase of 1.1%with placebo in pool 3 (all comparisons
p b 0.0001; Fig. 2A). For pools 1 and 2, dose increase to 150 mg Q2W at
Week 12 occurred in 18% and 35% of patients, respectively. At Week 24,
LDL-C was reduced with alirocumab 75/150 mg Q2W by 48.9% (vs.
19.3% with ezetimibe, Pool 1) and 48.6% (vs. a 4.2% increase with place-
bo, Pool 2), and was reduced with alirocumab 150 mg Q2W (Pool 3) by
60.4% (vs. a 0.5% increase with placebo, all comparisons p b 0.0001;
Fig. 2B). LDL-C reductions with alirocumab were observed fromWeek
4 and were maintained up to 78/104 weeks (Fig. 3). Across the three
pools, signiﬁcantly more patients achieved their risk-based LDL-C
goals with alirocumab (75–79% by Week 24) versus ezetimibe (52%)
or placebo (6–8%) (Fig. 4).
3.3. Changes in other lipid parameters
In addition to the LDL-C reductions, levels of non-HDL-C, apo B, and
Lp(a)were all signiﬁcantly reducedwith alirocumab (Fig. 5; p b 0.0001).
Signiﬁcant reductions in triglycerides were observed with alirocumab
versus placebo in Pools 2 and 3 (10.3% and 17.0%, respectively, at
Week 24; p b 0.0001; Table 2). Reductions in triglycerides versus
ezetimibe were not signiﬁcant (Table 2, Pool 1). HDL-C and apo A1
levels increased modestly but signiﬁcantly (p b 0.0001) following
alirocumab treatment versus placebo and versus ezetimibe (Table 2).
3.4. Safety summary
Overall rates of TEAEs, serious adverse events, deaths, and discontin-
uations were similar between alirocumab and control groups (Table 3).
TEAEs occurringmore frequently (≥5.0%)with alirocumab versus place-
bo were nasopharyngitis (12.6% vs. 12.1%), inﬂuenza (6.3% vs. 5.4%), di-
arrhea (5.3% vs. 4.9%), and injection site reaction (7.2% vs. 5.3%); those
occurring more frequently with placebo versus alirocumab were upper
respiratory tract infection (8.0% vs. 7.0%), back pain (6.0% vs. 5.3%),
headache (5.5% vs. 5.1%), and arthralgia (6.5% vs. 5.1%). TEAEs with a
higher incidence in the alirocumab versus ezetimibe groups were
upper respiratory tract infection (7.7% vs. 6.8%), headache (5.0% vs.
3.6%), hypertension (5.5% vs. 5.2%), and injection site reaction (2.6% vs.
1.1%); those occurring with higher incidence in the ezetimibe versus
alirocumab groups were nasopharyngitis (5.2% vs. 4.7%) and dizziness
(5.4% vs. 4.8%). In alirocumab- and ezetimibe-treated patients, 0.3%
and 0.2% permanently discontinued due to injection site reaction; corre-
sponding numbers for alirocumab versus placebo were 0.2% and 0.3%.
4. Discussion
This pooled analysis included 4629 high CV risk patients from eight
Phase 3 trials whose LDL-C levels were inadequately controlled despite
maximally tolerated background statin with or without other LLTs. The
majority of patients (73%) had a history of ASCVD, and a large propor-
tion had HeFH (28.1%) or diabetes (31.5%). In this cohort of patients,
the addition of alirocumab signiﬁcantly reduced LDL-C levels versus
ezetimibe or placebo controls (48.6–60.4% across the pools at Week
24, p b 0.0001 versus control), and LDL-C reductions were maintained
for the duration of treatment, up to 104 weeks. Across all three pools,
consistent signiﬁcant reductions with alirocumab were also observed
in atherogenic lipid parameters, non-HDL-C, apo B, and Lp(a), at Week
24. The alirocumab treatment effect on Lp(a) (17.4–25.1% reductionvs. control) contrasted with that of statin therapy, which appears to
have had little or no effect on this parameter [16,17]. Modest reductions
in triglycerides and increases in HDL and apo A1 were also seen in
alirocumab-treated patients.
In six of the eight studies analyzed, individuals received maximally
tolerated statins (accounting for 91% of the total number of individuals
included in the pooled dataset). Overall, 58.4% of all participants were
tolerant of high-dose statins (deﬁned as atorvastatin 40–80 mg,
rosuvastatin 20–40 mg, or simvastatin 80 mg) at study entry and as
background therapy throughout the trial period; the remainder
received lower doses (as per protocol with an investigator-approved
reason, e.g. myalgia). However, baseline data demonstrated a need for
further LLT, particularly for those individuals who did not achieve
their LDL-C targets orwhowere unable to tolerate higher doses of statin
therapy. In this high CV risk population, baseline mean LDL-C levels for
all pools were N105 mg/dL, conﬁrming the extent of the unmet need in
these patients, despite statin therapy. Individuals in Pool 2 had the
greatest unmet need, with the highest LDL-C levels at study entry
(mean 129–130 mg/dL).
Studies in this pooled analysis were grouped by starting dose of
alirocumab. Pools 1 and 2 had a lower starting dose of alirocumab
(75 mg Q2W) than Pool 3 (alirocumab 150 mg Q2W). In Pools 1 and
2,Week 12 results gave an estimate of the efﬁcacy of the two doses sep-
arately, before potential per-protocol dose increase. Signiﬁcant reduc-
tions in LDL-C were observed from as early as 12 weeks; at this point,
LDL-C was reduced by 44.5–49.2% from baseline with alirocumab
75 mg Q2W and by 62.6% with 150 mg Q2W. Improvements in other
lipid parameters were also observed. At Week 12, the proportion of
patients in the placebo-controlled pool who required a dose increase
(35%) was higher than for the ezetimibe-controlled pool (18%). This is
likely due to the higher proportion of HeFH patients having higher
mean baseline LDL-C levels in the placebo-controlled pool.
The beneﬁt of having two starting alirocumab doses is that it allows
for ﬂexibility and individualization of therapy based on each patient's
LDL-C levels and treatment goals. For example, for those with
inadequately controlled LDL-C levels (e.g. ≥160 mg/dL in the HIGH FH
study) it may be appropriate to initiate treatment with 150 mg
alirocumab Q2W, while those with lower LDL-C levels can be started
on a lower dose of 75 mg Q2W, with the potential to increase the dose
to 150 mg Q2W if goals are not met.
The pooled alirocumab efﬁcacy data presented is consistent with
that observed in other patient populations. Previously, alirocumab has
signiﬁcantly reduced LDL-C levels in studies performed without
background statin (45% reduction with alirocumab [n = 126] versus
15% with ezetimibe [n = 125] in the ALTERNATIVE trial [18], and 47%
[n = 52] versus 16% [n = 51], respectively, in the MONO trial [15]). In
addition, overall safety data from the present pooled analysis demon-
strated similar tolerability compared with the control groups and
previous studies. The increased incidence of injection site reactions is
considered to be related to alirocumab treatment, althoughmost events
reported have been rated as mild in severity and self-rate limiting [5,6].
The percentage of alirocumab-treated patients discontinuing due to
injection site reactions was very low (≤0.3%).
Statin therapy, with or without other LLT, can reduce the risk of CV
disease in high-risk patients, but tolerability and compliance issues
may contribute to many patients failing to achieve desired LDL-C levels
[19]. In other large scale trials, such as IMPROVE-IT (conducted in
patients following acute coronary syndrome), lowering of LDL-C levels
by approximately 24% was shown to signiﬁcantly improve CV
outcomes, and reductions below target levels conferred additional
beneﬁts [20]. In earlier studies using intensive statin therapy such as
PROVE-IT [21] and TNT [22], LDL-C levels of 62 mg/dL and 77 mg/dL,
were achieved with 80 mg atorvastatin. In the present analysis where
alirocumab was added to the existing statin regimen (±other LLT),
mean LDL-C levels of below the 70 mg/dL were achieved across all
pools (Week 24, Pool 1, 54 mg/dL; Pool 2, 65 mg/dL; Pool 3,
Table 1
Baseline characteristics of randomized patients by analysis pool.
Pool 1
Alirocumab 75/150 mg Q2W versus
ezetimibe (n = 1130)
Pool 2
Alirocumab 75/150 mg Q2W versus
placebo (n = 1051)
Pool 3
Alirocumab 150 mg Q2W versus
placebo (n = 2448)
Alirocumab
(n = 686)
Ezetimibe
(n = 444)
Alirocumab
(n = 699)
Placebo
(n = 352)
Alirocumab
(n = 1625)
Placebo
(n = 823)
Age, years, mean (SD) 61.6 (9.7) 62.3 (9.7) 55.6 (12.9) 55.5 (12.5) 60.0 (10. 8) 60.2 (10.6)
Males, n (%) 483 (70.4) 294 (66.2) 397 (56.8) 216 (61.4) 1018 (62.6) 496 (60.3)
Race, white, n (%) 582 (84.8) 385 (86.7) 634 (90.7) 312 (88.6) 1505 (92.6) 760 (92.3)
BMI, kg/m2, mean (SD) 30.3 (5.9) 30.7 (5.6) 30.0 (5.5) 30.1 (6.0) 30.1 (5.7) 30.5 (5.4)
HeFH, n (%) 26 (3.8) 18 (4.1) 490 (70.1) 245 (69.6) 348 (21.4) 174 (21.1)
Diabetes, n (%) 243 (35.4) 166 (37.4) 132 (18.9) 71 (20.2) 564 (34.7) 284 (34.5)
Cardiovascular disease history
ASCVD, n (%) 580 (84.5) 353 (79.5) 395 (56.5) 200 (56.8) 1219 (75.0) 634 (77.0)
CHD, n (%) 547 (79.7) 336 (75.7) 368 (52.6) 192 (54.5) 1086 (66.8) 574 (69.7)
ACS, n (%) 401 (58.5) 241 (54.3) 245 (35.1) 134 (38.1) 734 (45.2) 394 (47.9)
Coronary revascularization procedure, n (%) 410 (59.8) 253 (57.0) 281 (40.2) 140 (39.8) 724 (44.6) 382 (46.4)
Other clinically signiﬁcant CHD, n (%) 265 (38.6) 176 (39.6) 152 (21.7) 79 (22.4) 465 (28.6) 243 (29.5)
PAD, n (%) 32 (4.7) 16 (3.6) 17 (2.4) 13 (3.7) 80 (4.9) 43 (5.2)
Ischemic stroke, n (%) 55 (8.0) 31 (7.0) 39 (5.6) 10 (2.8) 160 (9.8) 76 (9.2)
Background therapy, n (%)
Use of any statin 685 (99.9) 444 (100.0) 698 (99.9) 352 (100.0) 1624 (99.9) 822 (99.9)
High-dose statina 328 (68.5) 165 (68.5) 541 (77.4) 282 (80.1) 784 (48.2) 396 (48.1)
Non-statin LLT 74 (10.8) 54 (12.2) 395 (56.5) 217 (61.6) 453 (27.9) 233 (28.3)
Baseline lipid parameters, mg/dL
Calculated LDL-C, mean (SD) 109.4 (35.6) 105.0 (36.2) 129.0 (47.3) 130.3 (45.4) 125.9 (45.9) 125.3 (44.5)
Non-HDL-C, mean (SD) 139.3 (39.7) 135.4 (41.8) 155.5 (50.0) 155.8 (48.4) 155.8 (49.4) 155.4 (48.6)
Apo B, mean (SD) 94.3 (23.0) 92.3 (23.5) 106.1 (29.3) 105.6 (27.8) 103.5 (28.9) 103.3 (28.8)
Lp(a), median (Q1:Q3) 26.0 (8.0:74.0) 24.0 (10.0:61.0) 29.0 (10.0:81.0) 26.0 (8.0:75.0) 22.2 (7.7:66.1) 21.5 (6.7:66.8)
Triglycerides, median (Q1:Q3) 129.0 (96.0:185.0) 134.0 (97.0:187.0) 114.0 (85:161) 111.0 (86:156) 132.0 (94:182) 134.5 (95:189)
HDL-C, mean (SD) 48.0 (13.2) 48.3 (13.2) 50.5 (15.4) 49.7 (14.4) 49.8 (12.3) 49.8 (12.4)
Apo A1, mean (SD) 142.1 (23.8) 142.7 (24.7) 143.8 (27.3) 142.5 (27.1) 146.2 (25.1) 146.7 (27.2)
ACS, acute coronary syndrome (includes silent MI, acute MI, and unstable angina); Apo, apolipoprotein; ASCVD, atherosclerotic cardiovascular disease; BMI, body mass index; CHD, cor-
onary heart disease; HDL-C, high-density lipoprotein cholesterol; HeFH, heterozygous familial hypercholesterolemia; LDL-C, low-density lipoprotein cholesterol; LLT, lipid-lowering ther-
apy; Lp(a), lipoprotein (a); MI, myocardial infarction; PAD, peripheral artery disease; Q2W, every 2 weeks; SD, standard deviation.
a High-dose statin= atorvastatin 40–80mg, rosuvastatin 20–40mg, or simvastatin 80mg. Pool 1: COMBO II, OPTIONS I, and OPTIONS II; Pool 2: COMBO I, FH I, and FH II; Pool 3: LONG
TERM and HIGH FH.
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designed to prospectively analyze occurrence of CV events, however,
the effect of alirocumab on CV events is currently being assessed in
the large-scale (n = 18,000 patients) ODYSSEY OUTCOMES trial
(NCT01663402) [23].Fig. 2. LDL-Cpercentage reductions frombaseline toWeeks 12 (a) and24 (b)a. * p b 0.0001 vs. co
to treatment. b Dose increased from75 to 150mgQ2WatWeek 12 in 18% and 35% of patients in
LDL-C, low-density lipoprotein cholesterol; LS, least squares; PBO, placebo; Q2W, every 2 week5. Study limitations
The main limitation of this analysis is that it was a post hoc analysis
of pooled studies and, as a result of pooling, the patient population
covered a broad clinical spectrum, likely resulting in variations inntrol. a Intention-to-treat analysis, including all lipid data collected regardless of adherence
the ezetimibe- and placebo-controlled pools, respectively. ALI, alirocumab; EZE, ezetimibe,
s; SE standard error.
Fig. 3. LDL-C change over time (on-treatment population) (a) Pool 1; (b) Pool 2; (C) Pool 3.a * All p valuesb0.0001 vs. control. (aPool 1 COMBO II toWeek 104, OPTIONS I andOPTIONS II not
included due to shorter duration (Week 24); Pool 2 FH I and FH II toWeek 78, COMBO I not included due to shorter duration (52 weeks); Pool 3 LONG TERM and, HIGH FH, both studies
shown to Week 78.). LDL-C, low-density lipoprotein cholesterol; LS, least squares; SE standard error.
754 M. Farnier et al. / International Journal of Cardiology 223 (2016) 750–757baseline characteristics. However, while data from an individual study
provide information about a single study scenario, this pooled analysis
of larger numbers of patients accumulated across the studies allows
visualization of the data across different trial design elements (includingFig. 4. Achievement of risk-based LDL-C goalsa at Week 12 (a) and 24 (b)b. * p b 0.0001 vs. con
patients with high CV risk. Very high CV risk was deﬁned as patients with CHD or CHD risk e
treat analysis. ALI, alirocumab; CHD, coronary heart disease; CV, cardiovascular; EZE, ezetimibepatient population, dose regimen, control arm, and use of background
LLTs). In addition to allowing further characterization of the data, the
results also conﬁrm the generalizability and consistency of the drug
effect in less frequently represented subgroups in these studies.trol. a LDL-C goals were b70 mg/dL for patients at very high CV risk, and b100 mg/dL for
quivalents. High CV risk was deﬁned as all other patients in these studies. b intention-to-
, LDL-C, low-density lipoprotein cholesterol; PBO, placebo.
Fig. 5. Percentage changes in non-HDL-C, apo B, and Lp(a), at Week 12 (A, C, and E, respectively) and Week 24 (B, D, and F, respectively)a. * p b 0.0001 vs. control. a Intention-to-treat
analysis. Apo, apolipoprotein; ALI, alirocumab; EZE, ezetimibe, HDL-C, high-density lipoprotein cholesterol; Lp(a), lipoprotein (a); LS, least squares; PBO, placebo; SE, standard.
755M. Farnier et al. / International Journal of Cardiology 223 (2016) 750–7576. Conclusions
In summary, inhighCV riskpatients onmaximally-tolerated statin±
other LLT, alirocumab (75 or 150 mg Q2W) demonstrated signiﬁcant
LDL-C reductions versus controls, ranging from 47% to 60% according
to study designs. Mean LDL-C levels below target levels of ≤70/
≤100 mg/dL (dependent on CV risk) were achieved in all pools and sig-
niﬁcant improvements were seen in non-HDL-C, apo B, Lp(a), and otherlipid parameters. Overall safety was comparable with controls, with a
higher rate of injection site reactions with alirocumab.
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